Behavioral Counseling and Varenicline Treatment for Smoking Cessation

American Journal of Preventive Medicine

Volumn 38, Issue 5, 2010, Pages 482-490

  Swan, Gary E ^a   McClure, Jennifer B ^b   Jack, Lisa M ^a   Zbikowski, Susan M ^c   Javitz, Harold S ^a   Catz, Sheryl L ^b   Deprey, Mona ^c   Richards, Julie ^b   McAfee, Timothy A ^c  

^a SRI INTERNATIONAL   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c Free and Clear Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

ABSTINENCE; ADULT; ARTICLE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SELF REPORT; SMOKING CESSATION; TELECONSULTATION;

ADULT; BENZAZEPINES; COUNSELING; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; NICOTINIC AGONISTS; OUTCOME ASSESSMENT (HEALTH CARE); QUINOXALINES; SMOKING CESSATION; TELEPHONE; WASHINGTON;

EID: 77950814384     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2010.01.024     Document Type: Article

References (37)

1. Stead L.F., Perera R., and Lancaster T. Telephone counseling for smoking cessation. Cochrane Database Syst Rev 3 (2006) CD002850
2. Fiore M.C., Jaén C.R., and Baker T.B. Treating tobacco use and dependence: 2008 update. Clinical practice guideline (May 2008), USDHHS Public Health Service, Rockville MD
3. Cobb N.K., Graham A.L., Bock B.C., Papandonatos G., and Abrams D.B. Initial evaluation of a real-world Internet smoking cessation system. Nicotine Tob Res 7 2 (2005) 207-216
4. Graham A.L., Cobb N.K., Raymond L., Sill S., and Young J. Effectiveness of an Internet-based worksite smoking cessation intervention at 12 months. J Occup Environ Med 49 8 (2007) 821-828
5. Saul J.E., Schillo B.A., Evered S., et al. Impact of a statewide Internet-based tobacco cessation intervention. J Med Internet Res 9 3 (2007) e28
6. Etter J.F. Comparing the efficacy of two Internet-based, computer-tailored smoking cessation programs: a randomized trial. J Med Internet Res 7 1 (2005) e2
7. Japuntich S.J., Zehner M.E., Smith S.S., et al. Smoking cessation via the Internet: a randomized clinical trial of an Internet intervention as adjuvant treatment in a smoking cessation intervention. Nicotine Tob Res 8 1S (2006) S59-S67
8. Pike K.J., Rabius V., McAlister A., and Geiger A. American Cancer Society's QuitLink: randomized trial of Internet assistance. Nicotine Tob Res 9 3 (2007) 415-420
9. Strecher V.J., McClure J.B., Alexander G.L., et al. Web-based smoking-cessation programs: results of a randomized trial. Am J Prev Med 34 5 (2008) 373-381
10. Strecher V.J., Shiffman S., and West R. Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction 100 5 (2005) 682-688
11. Nides M., Oncken C., Gonzales D., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166 15 (2006) 1561-1568
12. Oncken C., Gonzales D., Nides M., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166 15 (2006) 1571-1577
13. Niaura R., Hays J.T., Jorenby D.E., et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 24 7 (2008) 1931-1941
14. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 1 (2006) 47-55
15. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 1 (2006) 56-63
16. Nakamura M., Oshima A., Fujimoto Y., Maruyama N., Ishibashi T., and Reeves K.R. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 29 6 (2007) 1040-1056
17. Tsai S.T., Cho H.J., Cheng H.S., et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 29 6 (2007) 1027-1039
18. Tonstad S., Tonnesen P., Hajek P., Williams K.E., Billing C.B., and Reeves K.R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296 1 (2006) 64-71
19. Hollis J.F., McAfee T.A., Fellows J.L., Zbikowski S.M., Stark M., and Riedlinger K. The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tob Control 16 1S (2007) i53-i59
20. Orleans C.T., Schoenbach V.J., Wagner E.H., et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. J Consult Clin Psychol 59 3 (1991) 439-448
21. Swan G.E., McAfee T., Curry S.J., et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 163 19 (2003) 2337-2344
22. U.S. Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline) (2008). www.fda.gov/cder/drug/advisory/varenicline.htm
23. Leabman M.K., Huang C.C., Stryke D., et al. PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2). Pharmacol Rev 55 3 (2003) 399
24. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerström K.O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 9 (1991) 1119-1127
25. Cohen S., and Lichtenstein E. Perceived stress, quitting smoking, and smoking relapse. Health Psychol 9 4 (1990) 466-478
26. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (2000), American Psychological Association, Washington DC
27. Derogatis L.R., Lipman R.S., Rickels K., Uhlenhuth E.H., and Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 19 1 (1974) 1-15
28. Ward M.M., Swan G.E., and Jack L.M. Self-reported abstinence effects in the first month after smoking cessation. Addict Behav 26 3 (2001) 311-327
29. Curry S.J., Grothaus L.C., McAfee T., and Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 339 10 (1998) 673-679
30. El-Bastawissi A., McAfee T., Zbikowski S.M., et al. The uninsured and Medicaid Oregon tobacco user experience in a real-world, phone-based cessation programme. Tob Control 12 1 (2003) 45-51
31. Ringen K., Anderson N., McAfee T., Zbikowski S.M., and Fales D. Smoking cessation in a blue-collar population: results from an evidence-based pilot program. Am J Ind Med 42 5 (2002) 367-377
32. McClure J.B., Swan G.E., Jack L., et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 24 5 (2009) 563-569
33. Glasgow R.E., Mullooly J.P., Vogt T.M., et al. Biochemical validation of smoking status: pros, cons, and data from four low-intensity intervention trials. Addict Behav 18 5 (1993) 511-527
34. Patrick D.L., Cheadle A., Thompson D.C., Diehr P., Koepsell T., and Kinne S. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health 84 7 (1994) 1086-1093
35. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 4 2 (2002) 149-159
36. Cahill K., Stead L.F., and Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 3 (2008) CD006103
37. Schroeder S.A., and Sox H.C. Trials that matter: varenicline: a designer drug to help smokers quit. Ann Intern Med 145 10 (2006) 784-785